All In Biotech

Drug Trial Radar · NCT02139046

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout

A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout

Last checked: Nov 19, 2026Latest source record: Nov 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,790 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,790

Actual

Start

Apr 2014

Primary completion

Nov 2015

Study completion Nov 2015

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
May 15, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in participants with gout.

Conditions

  • Gout

Interventions

  • Febuxostat IRDrug

    Febuxostat IR over-encapsulated tablets

  • Febuxostat XRDrug

    Febuxostat XR over-encapsulated capsules

  • Febuxostat placeboDrug

    Febuxostat placebo-matching capsules

  • ColchicineDrug

    Colchicine tablets

  • NaproxenDrug

    Naproxen tablets

  • LansoprazoleDrug

    Lansoprazole capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3Time frame: Month 3

Locations

192 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Binghamton, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Gilbert, Arizona

  • Site not named

    Glendale, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Fayetteville, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Searcy, Arkansas

  • Site not named

    Bellflower, California

  • Site not named

    Carmichael, California

  • Site not named

    Costa Mesa, California

  • Site not named

    Covina, California

  • Site not named

    El Cajon, California

  • Site not named

    Encinitas, California

  • Site not named

    Encino, California

  • Site not named

    Escondido, California

  • Site not named

    Gold River, California

  • Site not named

    Irvine, California

  • Site not named

    Lancaster, California

  • Site not named

    Lomita, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Monterey Park, California

  • Site not named

    Murrieta, California

  • Site not named

    North Hollywood, California

  • Site not named

    Norwalk, California

  • Site not named

    Paramount, California

  • Site not named

    Rancho Cucamonga, California

  • Site not named

    Riverside, California

  • Site not named

    Roseville, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Jose, California

  • Site not named

    San Ramon, California

  • Site not named

    Santa Clarita, California

  • Site not named

    Tustin, California

  • Site not named

    Upland, California

  • Site not named

    Arvada, Colorado

Showing 40 of 192 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.